Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to assess which patients with metastatic triple-negative breast cancer could benefit from imm…
The development of CAR-T technology in recent years has been a major milestone in the fight against cancer. These sort of “living drugs”—T-cells modified to expand, recognize and attack cancer cells within the body—offer hope to many patients after rel…
A new study from MUSC Hollings Cancer Center researchers shows, for the first time, that a receptor called PPAR δ, or peroxisome proliferator-activated receptor delta, is an important player in a pathway that disables the immune system so that T-cells …
Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity. The pre-clinical findings, published in Nature, highlight the po…
A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a study by researchers from the Johns Hopkins Kimmel …
In 1893, the American Journal of the Medical Sciences reported on 10 patients whose large and hitherto incurable cancers had been injected with bacteria taken from skin infections. In every case, striking improvement was seen, marking the birth of “can…
Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The work, published Oct. 23 in Nature, points toward a promising new im…
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a ‘magic bullet’ strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.
Dermatofibrosarcoma protuberans (DFSP) is a rare skin sarcoma known for its high recurrence rates, making treatment particularly challenging. While surgery remains the standard option, it often leads to scarring and other complications.
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs. The design a…
